Research Advances in Application of CAR-NK Therapy for Acute Myeloid Leukemia

SU Shuai; XIAO Yi

doi:10.3971/j.issn.1000-8578.2026.25.0749

您当前的位置：

首页 >

文章列表页 >

Research Advances in Application of CAR-NK Therapy for Acute Myeloid Leukemia

更新时间：2026-11-05

- Research Advances in Application of CAR-NK Therapy for Acute Myeloid Leukemia
- Vol. 53, Issue 4, Pages: 281-288(2026)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.3971/j.issn.1000-8578.2026.25.0749
  CLC： R733.71
- Published：2026
- 稿件说明：
移动端阅览
苏帅, 肖毅. CAR-NK疗法在急性髓系白血病中的应用研究进展[J]. 肿瘤防治研究, 2026, 53(4): 281-288.

SU Shuai, XIAO Yi. Research Advances in Application of CAR-NK Therapy for Acute Myeloid Leukemia[J]. 2026, 53(4): 281-288.
苏帅, 肖毅. CAR-NK疗法在急性髓系白血病中的应用研究进展[J]. 肿瘤防治研究, 2026, 53(4): 281-288. DOI： 10.3971/j.issn.1000-8578.2026.25.0749.

SU Shuai, XIAO Yi. Research Advances in Application of CAR-NK Therapy for Acute Myeloid Leukemia[J]. 2026, 53(4): 281-288. DOI： 10.3971/j.issn.1000-8578.2026.25.0749.

摘要

嵌合抗原受体T细胞（CAR-T）免疫疗法在B系血液系统肿瘤中已取得突破性进展，然而在急性髓系白血病（AML）中，因缺乏高度特异的肿瘤抗原，且部分靶点在正常造血干/祖细胞上同样表达，其疗效与可控性受限，因此可能出现显著的骨髓抑制及细胞因子释放综合征（CRS）等不良反应。相较之下，CAR-NK细胞免疫疗法作为一种新兴策略，依托NK细胞的天然抗肿瘤活性，表现出较低的CRS与移植物抗宿主病（GVHD）风险，早期临床研究亦提示其具有良好的安全性与抗肿瘤活性。本文聚焦CAR-NK疗法在AML治疗中的最新进展，并对未来发展趋势与潜在突破方向加以展望。

Abstract

Chimeric antigen receptor (CAR) T-cell therapy for B-cell hematologic malignancies has achieved breakthrough success; however

its efficacy for acute myeloid leukemia (AML) is constrained by the lack of highly specific tumor antigens and the expression of shared targets on normal hematopoietic stem/progenitor cells

increasing the risk of on-target myelosuppression and cytokine release syndrome (CRS). By contrast

CAR-NK cell therapy

an emerging strategy that leverages the innate antitumor activity of natural killer cells

is associated with low rates of CRS and graft-versus-host disease. Early clinical studies also indicate its favorable safety profile with preliminary antileukemic activity. This review summarizes recent advances in CAR-NK therapy for AML and discusses future directions and potential avenues for clinical translation.

关键词

Keywords

references

Gill S, Tasian SK, Ruella M, et al . Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells[J ] . Blood, 2014, 123(15): 2343-2354.

Wei W, Yang D, Chen X, et al . Chimeric antigen receptor T-cell therapy for T-ALL and AML[J ] . Front Oncol, 2022, 12: 967754.

Liu E, Marin D, Banerjee P, et al . Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors[J ] . N Engl J Med, 2020, 382(6): 545-553.

Saadh MJ, Torabi Fard N, Hussein A, et al . Mesenchymal stem cells in the bone marrow microenvironment: a double-edged sword for AML[J ] . J Cancer Res Clin Oncol, 2025, 151(6): 193.

Tang X, Yang L, Li Z, et al . First-in-man clinical tri al of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia[J ] . Am J Cancer Res, 2018, 8(6): 1083-1089.

Huang R, Wang X, Yan H, et al . Safety and efficacy of CD33-targeted CAR-NK cell therapy for relapsed/refractory AML: preclinical evaluation and phase Ⅰ trial[J ] . Exp Hematol Oncol, 2025, 14(1): 1.

Sauter CS, Borthakur G, Mountjoy L, et al . A Phase 1 Study of NKX101, a Chimeric Antigen Receptor Natural Killer (CAR-NK) Cell Therapy, with Fludarabine and Cytarabine in Patients with Acute Myeloid Leukemia[J ] . Blood, 2023, 142(Supplement 1): 2097.

Huang R, Li X, He Y, et al . Recent advances in CAR-T cell engineering[J ] . J Hematol Oncol, 2020, 13(1): 86.

Garrison B, Deng H, Yucel G, et al . Senti-202, a Selective, Off-the-Shelf, Preclinical CAR-NK Cell Therapy with CD33 and/or FLT3 Activating CAR, Healthy Cell Protection from Endomucin (EMCN) Inhibitory CAR and Calibrated Release IL-15 for Hematologic Malignancies Including AML[J ] . Blood, 2022, 140(Supplement 1): 4531-4532.

Perriello VM, Gionfriddo I, Rossi R, et al . CD123 Is Consistently Expressed on NPM1-Mutated AML Cells[J ] . Cancers (Basel), 2021, 13(3): 496.

Testa U, Riccioni R, Militi S, et al . Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis[J ] . Blood, 2002, 100(8): 2980-2988.

Fiorenza S, Turtle CJ. CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success[J]. BioDrugs, 2021, 35(3): 281-302.

Caruso S, De Angelis B, Del Bufalo F, et al . Safe and effective off-the-shelf immunotherapy based on CAR. CD123-NK cells for the treatment of acute myeloid leukaemia[J ] . J Hematol Oncol, 2022, 15(1): 163.

Rahnama R, Kizerwetter M, Yang H, et al . Single-chain variable fragment affinity tuning can optimize anti-AML CAR-NK cell functionality[J ] . J Immunother Cancer, 2025, 13(2): e010763.

Christodoulou I, Ho WJ, Marple A, et al . Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities[J ] . J Immunother Cancer, 2021, 9(12): e003894.

Soleimani Samarkhazan H, Zeht abcheh S, Seraji HR, et al . Unveiling the potential of CLL-1: a promising target for AML therapy[J ] . Biomark Res, 2025, 13(1): 28.

Zhang H, Bu C, Peng Z, et al . Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis[J ] . Leukemia, 2022, 36(11): 2596-2604.

Jin X, Zhang M, Sun R, et al . First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia[J ] . J Hematol Oncol, 2022, 15(1): 88.

Sedloev DN, Chen Q, Unglaub JM, et al . Structurally Optimized, IL-2-Armored CLL1 CAR-NK Cells Are Highly Potent Effectors Against AML without Hpsc Toxicity[J ] . Blood, 2024, 144 (Supplement 1): 3440.

Shi Y, Hao D, Qian H, et al . Natural killer cell-based cancer immunotherapy: from basics to clinical trials[J ] . Exp Hematol Oncol, 2024, 13(1): 101.

Kumar S, Mahendiran S, Nair RS, et al . A mechanistic, functional, and clinical perspective on targeting CD70 in cancer[J ] . Cancer Lett, 2024, 611: 217428.

Flieswasser T, Van Den Eynde A, Van Audenaerde J, et al . The CD70-CD27 axis in oncology: the new kids on the block[J ] . J Exp Clin Cancer Res, 2022, 41(1): 12.

Sauer T, Parikh K, Sharma S, et al . CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity[J ] . Blood, 2021, 138(4): 318-330.

Wang L, Wang Y, He X, et al . CD70-targeted iPSC-derived CAR-NK cells display potent function against tumors and alloreactive T cells[J ] . Cell Rep Med, 2025, 6(1): 101889.

Wolf Y, Anderson AC, Kuchroo VK. TIM3 comes of age as an inhibitory receptor[J]. Nat Rev Immunol, 2020, 20(3): 173-185.

Brunner AM, Esteve J, Porkka K, et al . Phase Ⅰb study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes[J ] . Am J Hematol, 2024, 99(2): E32-E36.

Klaihmon P, Samart P, Rojanasakul Y, et al . Anti-TIM3 chimeric antigen receptor-natural killer cells preferentially target primitive acute myeloid leukemia cells with minimal fratricide and exhaustion[J ] . Exp Hematol Oncol, 2024, 13(1): 67.

Klaihmon P, Luanpitpong S, Kang X, et al . Anti-TIM3 chimeric antigen receptor-natural killer cells from engineered induced pluripotent stem cells effectively target acute myeloid leukemia cells[J ] . Cancer Cell Int, 2023, 23(1): 297.

Gurney M, Stikvoort A, Nolan E, et al . CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide[J ] . Haematologica, 2022, 107(2): 437-445.

Lin Y, Xiao Z, Hu F, et al . Engineered CRO-CD7 CAR-NK cells derived from pluripotent stem cells avoid fratricide and efficiently suppress human T-cell malignancies[J ] . J Hematol Oncol, 2025, 18(1): 57.

Ran GH, Lin YQ, Tian L, et al . Natural killer cell homing and trafficking in tissues and tumors: from biology to application[J ] . Signal Transduct Target Ther, 2022, 7(1): 205.

He X, Wang L, Zeng W, et al . Regulatable C-X-C chemokine receptor type 4 in iPSC-derived NK cells improves bone marrow chemotaxis and targeting resident tumor[J ] . Trends Biotechnol, 2025, 43(7): 1668-1689.

Ladikou EE, Chevassut T, Pepper CJ, et al . Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia[J ] . Br J Haematol, 2020, 189(5): 815-825.

Liu F, Tarannum M, Zhao Y, et al . One-Step Construction of Allogeneic CAR-NK Cells Preventing Rejection and Mediating Enhanced Anti-Tumor Responses[J ] . Blood, 2024, 144(Supplement 1): 915.

Wang H, Feng S, Zhu Y, et al . The tandem CD33-CLL1 CAR-T as an approach to treat acute myeloid leukemia[J ] . Blood Transfus, 2025, 23(4): 338-347.

Xie J, Liu XF, Zhou T, et al . Overexpressing natural killer group 2 member A drives natural killer cell exhaustion in relapsed acute myeloid leukemia[J ] . Signal Transduct Target Ther, 2025, 10(1): 143.

Carter JL, Hege K, Yang J, et al . Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy[J ] . Signal Transduct Target Ther, 2020, 5(1): 288.

D'silva SZ, Singh M, Pinto AS. NK cell defects: implication in acute myeloid leukemia[J]. Front Immunol, 2023, 14: 1112059.

Yang K, Zhao Y, Sun G, et al . Clinical application and prospect of immune checkpoint inhibitors for CAR-NK cell in tumor immunotherapy[J ] . Front Immunol, 2022, 13: 1081546.

Zhu H, Blum RH, Bernareggi D, et al . Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity[J ] . Cell Stem Cell, 2020, 27(2): 224-237. e6.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Tumor-Associated Macrophages in Esophageal Squamous Cell Carcinoma: Underlying Mechanisms and Targeted Therapy Perspectives

Research Progress of Multidimensional Immunomodulatory Factor ZG16 in Enhancing Antitumor Immune Responses

Correlation Between Gut Microbiota Characteristics and Immunotherapy Efficacy in Patients with Advanced Microsatellite Stable Gastrointestinal Tumors

Research Progress on Predictive Value of Inflammatory and Nutritional Indicators for Prognosis of Nasopharyngeal Carcinoma in the Era of Immunotherapy

Research Progress on Role and Mechanism of CKIP-1 in Tumor Immune Microenvironment

Related Author

SONG Wenya

ZUO Jing

NIE Longyan

FANG Xiongchao

GAO Peng

HAN Zhuo

FENG Zhibo

SONG Tianshuo

Related Institution

School of Medicine, Northwest University

Department of General Surgery, Tangdu Hospital, Air Force Medical University

Oncology Department of Wuhan Puren Hospital

Second Gastrointestinal Surgery Ward of Wuhan Puren Hospital

Department of Gastrointestinal Oncology Surgery, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology

AI问答

⁰